Research graph
References from Durable disease control following multidisciplinary treatment including pembrolizumab in POLE-mutated dedifferentiated endometrial carcinoma with brain metastases. Local targets link to admitted publications; unresolved targets remain external evidence.
Endometrial cancer.
10.1016/s0140-6736(22)00323-3 · 2022 · External reference
2020 WHO classification of female genital tumors.
10.1055/a-1545-4279 · 2021 · External reference
Integrated genomic characterization of endometrial carcinoma.
10.1038/nature12113 · 2013 · External reference
Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes.
10.1136/ijgc-2019-000465 · 2019 · External reference
Dedifferentiated endometrial carcinoma: a rare aggressive neoplasm—clinical, morphological and immunohistochemical features.
10.3390/cancers15215155 · 2023 · External reference
Beyond the boundaries: a case report of dedifferentiated endometrial carcinoma masquerading as a neurological disorder.
2025 · External reference
Pembrolizumab plus chemotherapy in advanced endometrial cancer.
10.1056/nejmoa2302312 · 2023 · External reference
Dostarlimab for primary advanced or recurrent endometrial cancer.
10.1056/nejmoa2216334 · 2023 · External reference
Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial.
10.1200/jco.23.02132 · 2024 · External reference
Real-world data analysis of genomic alterations detected by a dual DNA-RNA comprehensive genomic profiling test.
10.1111/cas.70071 · 2025 · External reference
TCGA molecular subgroups in endometrial undifferentiated/dedifferentiated carcinoma.
10.1007/s12253-019-00784-0 · 2020 · External reference
Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis.
10.1097/pas.0000000000000873 · 2017 · External reference
Long-term disease-free survival with chemotherapy and pembrolizumab in a patient with unmeasurable, advanced-stage dedifferentiated endometrial carcinoma.
10.1016/j.gore.2024.101380 · 2024 · External reference
Brain metastases from endometrial cancer: clinical characteristics, outcomes, and review of the literature.
10.1016/j.wneu.2020.11.087 · 2021 · External reference
Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report series.
10.3389/fonc.2025.1568137 · 2025 · External reference
Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts.
10.1158/1078-0432.ccr-15-2878 · 2016 · External reference
TCGA molecular subgroups in endometrial undifferentiated/dedifferentiated carcinoma.
10.1007/s12253-019-00784-0 · ExternalCitation · doi-reference
Long-term disease-free survival with chemotherapy and pembrolizumab in a patient with unmeasurable, advanced-stage dedifferentiated endometrial carcinoma.
10.1016/j.gore.2024.101380 · ExternalCitation · doi-reference
Brain metastases from endometrial cancer: clinical characteristics, outcomes, and review of the literature.
10.1016/j.wneu.2020.11.087 · ExternalCitation · doi-reference
Endometrial cancer.
10.1016/s0140-6736(22)00323-3 · ExternalCitation · doi-reference
Integrated genomic characterization of endometrial carcinoma.
10.1038/nature12113 · ExternalCitation · doi-reference
2020 WHO classification of female genital tumors.
10.1055/a-1545-4279 · ExternalCitation · doi-reference
Dostarlimab for primary advanced or recurrent endometrial cancer.
10.1056/nejmoa2216334 · ExternalCitation · doi-reference
Pembrolizumab plus chemotherapy in advanced endometrial cancer.
10.1056/nejmoa2302312 · ExternalCitation · doi-reference
Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis.
10.1097/pas.0000000000000873 · ExternalCitation · doi-reference
Real-world data analysis of genomic alterations detected by a dual DNA-RNA comprehensive genomic profiling test.
10.1111/cas.70071 · ExternalCitation · doi-reference
Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes.
10.1136/ijgc-2019-000465 · ExternalCitation · doi-reference
Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts.
10.1158/1078-0432.ccr-15-2878 · ExternalCitation · doi-reference
Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial.
10.1200/jco.23.02132 · ExternalCitation · doi-reference
Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report series.
10.3389/fonc.2025.1568137 · ExternalCitation · doi-reference
Dedifferentiated endometrial carcinoma: a rare aggressive neoplasm—clinical, morphological and immunohistochemical features.
10.3390/cancers15215155 · ExternalCitation · doi-reference
